Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice

Journal of Neurochemistry

Volumn 70, Issue 2, 1998, Pages 708-714

  Chapman, Shira ^a   Michaelson, Daniel M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Apolipoprotein E deficient mice; Cholinergic projections; Dopaminergic projections; Noradrenergic projections; Serotonergic projections

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SEROTONINERGIC NERVE CELL;

ANIMALIA;

EID: 0031933654     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70020708.x     Document Type: Article

References (22)

1. Chen Y., Lomnitski L., Michaelson D. M., and Shohami E. (1997) Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 80, 1255-1262.
2. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines I. L., and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein-E type-4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
3. Francis P. T., Cross A. J., and Bowen D. M. (1994) Neurotransmitters and neuropeptides, in Alzheimer's Disease (Terry R. D., Katzman R., and Bick K. L., eds), pp. 247-261. Raven Press, New York.
4. Geula C. and Mesulam M. M. (1994) Cholinergic systems and related neuropathological predilection patterns in Alzheimer's disease, in Alzheimer's Disease (Terry R. D., Katzman R., and Bick K. L., eds), pp. 263-291. Raven Press, New York.
5. Gordon I., Grauer E., Genis I., Sehayek E., and Michaelson D. M. (1995) Memory deficit and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci. Lett. 199, 1-4.
6. 3H]imipramine localization and relationship to serotonin transporter. J. Pharmacol. Exp. Ther. 252, 410-418.
7. Inzelberg R., Chapman J., Treves T. A., Asherov A., Kiperwasser S., Hilkewicz D., Virchovsky R., Klimowitzky S., and Korczyn A.D. (1997) Apolipoprotein E4 in Parkinson's disease and dementia: new data and data analysis of published studies. Alzheimers Dis. Assoc. Disord. (in press).
8. Karnovsky M. J. and Roots L. A. (1964) A direct cloning thiocholine method for cholinesterases. J. Hisrochem. Cytochem. 121, 219-222.
9. Koller W. C., Glatt J. L., and Hubble J. P. (1995) Apolipoprotein E genotype in Parkinson's disease with and without dementia. Ann. Neurol. 37, 242-245.
10. Mahley R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
11. Masliah E., Mallory M., Ge N., Alford M., Veinberg I., and Roses A. D. (1995) Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol. 136, 107-122.
12. 3H-GBR 12935. J. Neural Transm. Gen. Sect. 87, 1-14.
13. Nathan B. P., Chang K.-C., Bellosta S., Brisch E., Ge N., Mahley R. W., and Pitas R. E. (1995) The inhibitory effect of apolipoprotein E4 on neunte outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270, 19791-19799.
14. Paxinos G. and Butcher L. L. (1985) Organizational principles of the brain as revealed by choline acetyltransferase and acetylcholinesterase distribution and projections, in The Rat Nervous System, Vol. 1 (Paxinos G., ed), pp. 487-521. Academic Press, Orlando.
15. Plump A. S., Smith J. D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J. G., Rubin E. M., and Breslaw J. L. (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 16, 343-353.
16. Poirier J. (1994) Apolipoprotein E animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17, 525-530.
17. Poirier J., Baccichet A., Dea D., and Gauthier S. (1993) Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55, 88-90.
18. Poirier J., Delise M.-C., Quirion R., Auberts I., Farlow D., Lahiri D., Hui S., Bertrand P., Nalbantoglu J., and Grefix B. M. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92, 12260-12264.
19. Roses A. D. (1994) Apolipoprotein E is a genetic locus that affects the rate of Alzheimer's disease expression: β amyloid burden is a secondary consequence dependent on apoE genotype and duration of disease. J. Neuropathol. Exp. Neurol. 53, 429-437.
20. Saunders A. M., Strittmatter W. J., Schmechel D., St. George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Rosi B. A., Gusella J. F., Crapper-MacLachlan D. R., Alberts M. J., Hulelte C., Grain B., Goldgaber D., and Roses A. D. (1993) Association of apolipoprotein-E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472.
21. Slotnick B. M. and Leonard C. M. (1975) A Stereotaxic Atlas of the Albino Rat Forebrain, p. 173. DHEW Publication No. (ADM) 75-100, U.S. Department of Health, Education, and Welfare, Washington, D.C.
22. 3H]Nisoxetine: aradioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J. Pharmacol. Exp. Ther. 260, 427-436.